Dilon Technologies Inc.

Dilon Technologies Inc. is a medical device company headquartered in the United States, specializing in products that aid in the battle against breast cancer. The company, established in 1999, boasts a robust medical device portfolio, which includes the Navigator System, a renowned surgical gamma probe for radio-guided lymphatic mapping and tumor localization, the MarginProbe, a pioneering technology for precise microscopic margin assessment in breast cancer surgery, and the TrueView 100 Pro, a Specimen Radiography System (SRS) utilizing advanced radiography and automated software to accurately identify tumor lesions in resected or biopsied breast tissue. In December 2013, the company secured a $3.95M investment through Debt Financing, signifying the confidence of investors in Dilon Technologies' vision and the potential for its innovations in the healthcare and biotechnology sectors. The absence of specific investment backers suggests that the company may have pursued this financing independently or through private channels, indicating a strategic and self-sufficient approach to funding its operations and advancements in the fight against breast cancer.